The Dark Genome with Author Sudhakaran Prabakaran

We began this podcast back around the time the ENCODE project announced that much of the genome was biochemically active. The big science project was undoing the tidy idea of “junk DNA,” and not without controversy. But activity is not the same as purpose. On today’s show, we move past the question of whether the non-coding genome does something and ask a more ambitious one: why has evolution retained so much genomic material unless it carries adaptive potential?Theral speaks with Sudhakaran Prabakaran, computational biologist at Northeastern University and founder of NonExomics, about his provocative new book, “Eclipsed Horizons: Unveiling the Dark Genome.” Drawing on his lab’s work cataloging more than 250,000 non-canonical proteins, Prabakaran argues that regions outside traditional gene definitions are constantly generating novel open reading frames—previously unrecognized proteins that may shape adaptation, speciation, and disease.Chapters:(00:00) Identical Genomes, Wildly Different Fish(04:00) The Dark Proteome Wakes Up(10:00) Protein Pop-Up Shops(20:00) Homo Minimus and the Space Thought Experiment(30:00) Precision Medicine Beyond the ExomeFrom rapidly diversifying cichlid fishes to human accelerated regions (HARs) of the human genome linked to schizophrenia, he makes the case that protein birth and death is continuous, cheap, and exploratory. In his framing, the “dark genome” functions less like debris and more like a flexible evolutionary sandbox—capable of producing latent biological parts that can be deployed under stress or even extreme environments like spaceflight.The book goes beyond ENCODE’s demonstration of activity and asks what that activity is for, crossing into that taboo in biology, teleonomic analysis. Weaving together proteomics, evolutionary biology, information theory, and even speculative extensions into space biology, Prabakaran suggests that genomes may be structured not just to preserve past adaptations, but to enable future ones.For those of you staying put on the ground, the implications are very tangible for precision medicine. His company NonExomics is using non-canonical protein signatures to stratify cancer patients and refine difficult diagnoses, arguing that the next wave of biomarkers may lie outside the exome.Provocative? Certainly. Grounded in emerging proteomics tools and real clinical cases? Also yes. This conversation probes directly into that mysterious future of biology. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe